WO2024252017A1 - Novel process for producing lactobacillus rhamnosus - Google Patents
Novel process for producing lactobacillus rhamnosus Download PDFInfo
- Publication number
- WO2024252017A1 WO2024252017A1 PCT/EP2024/065885 EP2024065885W WO2024252017A1 WO 2024252017 A1 WO2024252017 A1 WO 2024252017A1 EP 2024065885 W EP2024065885 W EP 2024065885W WO 2024252017 A1 WO2024252017 A1 WO 2024252017A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- equal
- less
- lactobacillus rhamnosus
- fermentation
- fermentation broth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- the invention relates to a novel process for producing Lactobacillus rhamnosus and for producing a composition comprising Lactobacillus rhamnosus.
- the invention relates to such a composition comprising Lactobacillus rhamnosus, the use of such a composition in a food or beverage and the use of such a composition for medical purposes.
- Bacterial compositions having probiotic activity are becoming increasingly popular as a part of human and animal diet due to their beneficial health effects. These health benefits, in addition to supporting intestinal health and function, include repopulating the gut after antibiotic therapy, offsetting lactose intolerance, supporting the immune system and reducing cholesterol. Lactic acid bacteria, primarily from the Lactobacillus and Bifidobacterium genera, that can help improve or maintain intestinal health and function are often termed probiotic bacteria (also referred to herein as probiotics).
- Lactobacillus rhamnosus and especially Lactobacillus rhamnosus GG is one of the most popular probiotic bacteria.
- Pili also referred to as fimbria
- fimbria are small hair-like fibrous proteins that are present on the surface area of many bacteria.
- probiotics are preferably sold based on their count of colony forming units (CFU) per gram.
- the count of colony forming units (CFU) per gram is looked at by customers as a measure for the viability of the probiotic. Manufacturers of probiotics therefore consider it an advantage to have a high count of CFU/g in their product.
- the invention provides a process for the production of a Lactobacillus rhamnosus, wherein the process comprises the steps of:
- the invention provides a process for the production of a composition comprising a Lactobacillus rhamnosus, wherein the process comprises the steps of:
- the invention provides Lactobacillus rhamnosus cells, respectively Lactobacillus rhamnosus bacterial particles, or a composition comprising Lactobacillus rhamnosus cells, respectively Lactobacillus rhamnosus bacterial particles, obtained or obtainable by any one of the above processes.
- the invention provides Lactobacillus rhamnosus cells, respectively Lactobacillus rhamnosus bacterial particles, wherein equal to or more than 90% w/w, preferably equal to or more than 95% w/w, more preferably equal to or more than 99% w/w, yet more preferably equal to or more than 99.5% w/w, still more preferably equal to or more than 99.9% w/w and most preferably still more preferably equal to or more than 100.0% w/w of the bacterial particles have a particle size, as determined by laser diffraction particle size analysis, of equal to or less than 8.0 micrometer, preferably equal to or less than 7.5 micrometer, more preferably equal to or less than 7.0 micrometer, yet more preferably equal to or less than 6.5 micrometer and most preferably equal to or less than 6.0 micrometer preferably equal or less than 5.5, 5.0, 4.5, 4.0, 3.5, 3.0, 2.5, or 2.0 micrometer, and the cells
- the invention provides a composition comprising Lactobacillus rhamnosus cells, respectively Lactobacillus rhamnosus bacterial particles, wherein equal to or more than 90% w/w, preferably equal to or more than 95% w/w, more preferably equal to or more than 99% w/w, yet more preferably equal to or more than 99.5% w/w, still more preferably equal to or more than 99.9% w/w and most preferably still more preferably equal to or more than 100.0% w/w of the bacterial particles have a particle size, as determined by laser diffraction particle size analysis, of equal to or less than 8.0 micrometer, preferably equal to or less than 7.5 micrometer, more preferably equal to or less than 7.0 micrometer, yet more preferably equal to or less than 6.5 micrometer and most preferably equal to or less than 6.0 micrometer preferably equal or less than 5.5, 5.0, 4.5, 4.0, 3.5, 3.0, 2.5, or 2.0 micrometer
- the invention provides a composition for animal and/or human consumption, preferably a medicament or a food product or a beverage product, comprising: - the Lactobacillus rhamnosus cells, respectively Lactobacillus rhamnosus bacterial particles, as referred to above; or - the composition comprising Lactobacillus rhamnosus cells, respectively Lactobacillus rhamnosus bacterial particles, as referred to above.
- the invention provides a use of the Lactobacillus rhamnosus cells, respectively Lactobacillus rhamnosus bacterial particles, as referred to above or the composition comprising Lactobacillus rhamnosus cells, respectively Lactobacillus rhamnosus bacterial particles, as referred to above in the production of a food or beverage product.
- the invention provides a use of the Lactobacillus rhamnosus cells, respectively Lactobacillus rhamnosus bacterial particles, as referred to above or the composition comprising Lactobacillus rhamnosus cells, respectively Lactobacillus rhamnosus bacterial particles, as referred to above in a probiotic composition and/or for medical purposes and/or in or as a medicament, preferably for use as a medicament for the treatment of or for prevention of a disease or condition in or related to the animal or human gastro-intestinal tract.
- the bacterial surface per gram product can be increased and/or the bacterial particle size can be decreased and/or a the count of CFU/gram can be increased and/or viable cell count can be increased.
- the processes according to the invention lead to a synergetic effect resulting in a high count of CFU/gram and a small particle size. Together the high count of CFU/gram and the small particle size lead to a high overall bacterial particle surface area per gram product.
- the pili on the cells may become less intertangled and more bioavailable.
- the invention is illustrated by the following figures: shows the bacterial particle size distribution of Lactobacillus rhamnosus GG for the samples derived from fermentors B1 and C2 as illustrated in the examples.
- shear (“black line”) allows for a substantial reduction in % volume with a particle size of more than 5 micrometer (pm) and the second peak of this line for fermentor C2 (according to the invention) is substantially lower (below 2 %), than the second peak of this line for fermentor B1 (comparative, above 2 %).
- the compound in principle includes all enantiomers, diastereomers and cis/trans isomers of that compound that may be used in the particular aspect of the invention; in particular when referring to such as compound, it includes the natural isomer(s).
- milk is intended to encompass milks from mammals and plant sources or mixtures thereof.
- Mammals sources of milk include, but are not limited to cow, sheep, goat, buffalo, camel, llama, horse or reindeer.
- Plant sources of milk include, but are not limited to, milk extracted from soy bean, pea, peanut, barley, rice, oat, quinoa, almond, cashew, coconut, hazelnut, hemp, sesame seed and sunflower seed.
- milk refers to not only whole milk, but also skim milk or any liquid component derived thereof or reconstituted milk.
- lactic acid bacteria is a general term for a class of non-spore forming, gram-positive bacteria whose main product of fermented sugar is lactic acid.
- probiotic bacteria include LAB bacteria of species of Lactobacillus, Bifidobacterium sp, and Saccharomyces. Lactobacillus rhamnosus is one of the most popular probiotic bacteria.
- the Lactobacillus rhamnosus is one or more of Lactobacillus rhamnosus GG, Lactobacillus rhamnous BD0016 and/or Lactobacillus rhamnous KF 7.
- Lactobacillus rhamnosus in all the aspects of this invention is Lactobacillus rhamnosus GG.
- Lactobacillus rhamnosus GG is officially also referred to as Lacticaseibacillus rhamnosus GG. The terms are used herein interchangeably.
- Lactobacillus rhamnosus GG is herein understood to refer to the Lactobacillus rhamnosus strain deposited at the American Type Culture Collection as ATCC 53103 by Sherwood Gorbach and Barry Goldin, or a mutant or variant thereof.
- the Lactobacillus rhamnosus in all the aspects of this invention is the Lactobacillus rhamnosus GG strain deposited as ATCC 53103.
- the Lactobacillus rhamnosus may be present as Lactobacillus rhamnosus bacterial particles, where each bacterial particle may comprise one or more cells.
- the processes according to the invention can allow one to reduce the bacterial particle size and increase the bacterial surface.
- the Lactobacillus rhamnosus as present in the compositions according to the invention comprises or consists of Lactobacillus rhamnosus bacterial particles, which bacterial particles preferably comprise or consist of equal to or less than 100 cells per particle, more preferably equal to or less than 50 cells per particle, still more preferably equal to or less than 20 cells per particle, even more preferably equal to or less than 10 cells per particle and yet more preferably equal to or less than 5 cells per particle.
- the Lactobacillus rhamnosus as present in the compositions according to the invention comprises or consists of Lactobacillus rhamnosus bacterial particles, which bacterial particles comprise or consist of equal to or less than 3 cells per particle.
- step (a) of the processes according to the invention the Lactobacillus rhamnosus GG is fermented in a lactose-free, preferably milk-free, medium in a fermentor, and a fermentation broth is removed from such fermentor.
- the fermentor may comprise or consist of a fermentation reactor, also sometimes referred to as a fermentation vat or a fermentation tank.
- the fermentor may or may not comprise a bubbling system and be a bubble reactor; may or may not comprise a stirrer and be a stirred reactor; and/or may or may not comprise a loop and be a loop reactor. Combinations are also possible.
- the stirrer is preferably operated at a stirring rate in the range from equal to or more than 1 round per minute (rpm), more preferably from equal to or more than 2 rounds per minute (rpm), yet more preferably from equal to or more than 5 rounds per minute (rpm), and even more preferably from equal to or more than 10 rounds per minute (rpm) to equal to or less than 500 rounds per minute (rpm), more preferably equal to or less than 300 rounds per minute (rpm), yet more preferably equal to or less than 200 rounds per minute (rpm), still more preferably equal to or less than 100 rounds per minute (rpm) and most preferably equal to or less than 50 rounds per minute (rpm).
- the fermentor may comprise a volume in the range from equal to or more than 1 liter, more preferably equal to or more than 5 liter to equal to or less than 50 liters. More preferably the fermentor is an industrial fermentor. Hence, more preferably the fermentor is a fermentor having a volume of equal to or more than 50 liter, more preferably equal to or more than 100 liter, still more preferably equal to or more than 500 liter and most preferably equal to or more than 1000 liter and preferably equal to or less than 700000 liter, more preferably equal to or less than 500000 liter and even more preferably equal to or less than 250000 liter, still more preferably equal to or less than 100000 liter.
- the Lactobacillus rhamnosus is suitably fermented in a medium in the fermentor.
- This medium may also be referred to herein as the fermentation medium.
- the medium can suitably be a solution, suspension or dispersion.
- the fermentation medium is an aqueous fermentation medium.
- the medium is an aqueous solution, suspension or dispersion.
- the fermentation medium may comprise a volume in the range from equal to or more than 1 liter, more preferably equal to or more than 5 liter to equal to or less than 50 liters. More preferably the fermentor is an industrial fermentor.
- the fermentation medium has a volume of equal to or more than 50 liter, more preferably equal to or more than 100 liter, still more preferably equal to or more than 500 liter and most preferably equal to or more than 1000 liter and preferably equal to or less than 700000 liter, more preferably equal to or less than 500000 liter and even more preferably equal to or less than 250000 liter, still more preferably equal to or less than 100000 liter.
- the medium has to be lactose-free.
- lactose-free is herein understood that preferably the fermentation medium comprises equal to or less than 1000 ppmw (parts per million by weight) lactose, more preferably equal to or less than equal to or less than 100 ppmw lactose, even more preferably equal to or less than 10 ppmw lactose, yet more preferably equal to or less than 1 ppmw lactose and still more preferably equal to or less than 0.1 ppmw lactose. Most preferably the medium does not comprise any measurable lactose and is completely lactose free.
- the medium is milk-deficient or milk-free.
- milk-free is herein understood that preferably the fermentation medium comprises equal to or less than 1000 ppmv (parts per million by volume) milk, more preferably equal to or less than equal to or less than 100 ppmv milk, even more preferably equal to or less than 10 ppmv milk, yet more preferably equal to or less than 1 ppmv milk and still more preferably equal to or less than 0.1 ppmv milk. Most preferably the medium does not comprise any measurable milk and is completely milk free.
- the term milk includes milk from a mammal source and/or a plantbased source.
- the fermentation medium preferably does not comprise any milk derived from cow, sheep, goat, buffalo, camel, llama, horse or reindeer and/or extracted from soy bean, pea, peanut, barley, rice, oat, quinoa, almond, cashew, coconut, hazelnut, hemp, sesame seed or sunflower seed.
- the fermentation medium is a solution, suspension or dispersion wherein the acetate is present as a disassociated or a non-disassociated calcium acetate salt and/or a disassociated or a non-disassociated ammonium acetate salt, most preferably as a disassociated or a non-disassociated ammonium acetate salt.
- the fermentation medium is stirrable, more preferably a stirrable liquid or slurry, and preferably the medium is not a solid or a gel.
- further details on the fermentation conditions are provided below.
- step (a) may produce, respectively result in, a fermentation broth.
- fermentation broth may suitably be removed from the fermentor before applying step (b).
- the medium also referred to herein as fermentation medium
- the glucose can be added as solid or as a solution.
- the glucose is added to the medium (also referred to herein as fermentation medium) in the form of an aqueous solution or aqueous suspension or aqueous dispersion comprising glucose.
- the glucose may for example be added to the medium (also referred to herein as fermentation medium) before the start of the fermentation and/or during the fermentation. If glucose is added during the fermentation such glucose is preferably added in a continuous manner, for example by in-line addition, for example via a loop reactor.
- medium also referred to herein as fermentation medium
- the glucose is present in the medium, for example at the start of the fermentation and/or during fermentation, in a concentration in the range from equal to or more than 20 gram/kilogram (gr/kg), preferably from equal to or more than 60 gram/kilogram (gr/kg), more preferably from equal to or more than 80 gr/kg, yet more preferably from equal to or more than 100 gr/kg, still more preferably from equal to or more than 110 gr/kg, to equal to or less than 600 gr/kg, more preferably to equal to or less than 400 gr/kg, even more preferably to equal to or less than 300 gr/kg, still more preferably to equal to or less than 200 gr/kg, yet more preferably to equal to or less than 170 gr/kg and most preferably equal to or less than 150 gr/kg, wherein gr/kg refers to the weight in grams of glucose per total weight in kilograms of medium.
- gr/kg refers to the weight in grams of glucose per total weight in kilograms of medium.
- the glucose is present in the medium, for example at the start of the fermentation and/or during fermentation, in a concentration in the range from equal to or more than 2% w/w, preferably from equal to or more than 6% w/w, more preferably from equal to or more than 8% w/w, yet more preferably from equal to or more than 10% w/w, still more preferably from equal to or more than 11 % w/w, to equal to or less than 60% w/w, more preferably to equal to or less than 40% w/w, even more preferably to equal to or less than 30% w/w, still more preferably to equal to or less than 20 % w/w, yet more preferably to equal to or less than 17% w/w and most preferably equal to or less than 15% w/w, based on the total weight of medium.
- the glucose is added as a solution, suspension or dispersion, the above ranges apply to the weight of the amount of glucose “as such” therein, not
- the fermentation in step (a) is further carried out in the presence of calcium.
- the calcium may be present as calcium element or as a salt. If the calcium is present as a salt, the calcium may be present in a disassociated form or a non-disassociated (i.e. an associated) form. That is, the calcium may for example be present as a Ca 2+ cation.
- the calcium is present or supplied to the medium (also referred to herein as fermentation medium) as a disassociated or a non-disassociated calcium salt.
- the fermentation medium comprises calcium or a calcium salt, suitably a disassociated or a non-disassociated calcium salt.
- the calcium salt is a halogenide salt of calcium, an organic acid salt of calcium or calciumhydroxide.
- the calcium salt is an halogenide salt of calcium, more preferably calcium chloride, calcium iodide or calcium bromide or a mixture thereof.
- the halogenide salt of calcium is calcium chloride.
- the calcium salt is an organic acid salt of calcium, preferably an organic acid salt comprising in the range from 1 to 6 carbon atoms, more preferably an organic salt comprising in the range from 1 to 4 carbon atoms.
- the organic acid salt of calcium is selected from the group consisting of calcium carbonate, calcium acetate, calcium propionate, calcium butanoate, calcium citrate, calcium gluconate or a mixture thereof. Most preferably the organic acid salt of calcium is calcium carbonate.
- the calcium is present or supplied to the medium as a disassociated or a non-disassociated calcium chloride salt and/or a disassociated or a non-disassociated calcium carbonate salt and/or a disassociated or a non-disassociated calciumhydroxide salt.
- the calcium is added to the medium in the form of an aqueous solution or aqueous suspension or aqueous dispersion comprising calcium, optionally as a Ca 2+ cation or otherwise as a disassociated or a non-disassociated salt.
- the fermentation medium comprises an aqueous solution or aqueous suspension or aqueous dispersion comprising calcium ora disassociated or a non-disassociated calcium chloride salt and/or a disassociated or a non-disassociated calcium carbonate salt and/or a disassociated or a non-disassociated calciumhydroxide salt, most preferably a disassociated or a nondisassociated calcium chloride salt.
- the calcium may for example be added to the medium (also referred to herein as fermentation medium) before the start of the fermentation and/or during the fermentation. If calcium is added during the fermentation such calcium is preferably added in a continuous manner, for example by in-line addition, for example via a loop reactor.
- the calcium is present in the medium, for example at the start of the fermentation and/or during fermentation, in a concentration in the range from equal to or more than 10 milligram/kilogram (mg/kg), preferably from equal to or more than 20 mg/kg, more preferably from equal to or more than 30 mg/kg, still more preferably from equal to or more than 40 mg/kg, to equal to or less than 10 gr/kg, more preferably to equal to or less than 5 gr/kg, even more preferably to equal to or less than 1 gr/kg, still more preferably to equal to or less than 500 mg/kg, yet more preferably to equal to or less than 300 mg/kg and most preferably equal to or less than 200 mg/kg, wherein gr/kg, respectively mg/kg, refers to the weight in grams, respectively milligrams, of calcium per total weight in kilograms of medium.
- Mg/kg milligram/kilogram
- the calcium is present in the medium, for example at the start of the fermentation and/or during fermentation, in a concentration in the range from equal to or more than 10 ppmw (parts per million by weight), preferably from equal to or more than 20 ppmw, more preferably from equal to or more than 30 ppmw, still more preferably from equal to or more than 40 ppmw, to equal to or less than 10% w/w, more preferably to equal to or less than 5% w/w, even more preferably to equal to or less than 1 .0% w/w, still more preferably to equal to or less than 500 ppmw, yet more preferably to equal to or less than 300 ppmw and most preferably equal to or less than 200 ppmw, based on the total weight of medium.
- 10 ppmw parts per million by weight
- a very high amount calcium may be less preferred as depending on the circumstances such may lead to precipitation.
- the risk of precipitation is highest with calcium carbonate.
- Calcium carbonate unfortunately has a very low solubility in pure water (about 15 mg/L, corresponding to about 0.0015% w/w at 25°C). Therefore most preferably any calcium salt is not present as calcium carbonate.
- any calcium salt is calcium chloride.
- the calcium may be added and/or present within the medium, for example at the start of the fermentation and/or during fermentation, in a concentration in the range from equal to or more than 0.0001 % w/w, more preferably from equal to or more than 0.001 % w/w, to equal to or less than 0.1 % w/w, more preferably equal to or less than 0.05% w/w, based on the total weight of the medium.
- the fermentation medium comprises in the range from equal to or more than 0.0001 % w/w, more preferably from equal to or more than 0.001 % w/w, to equal to or less than 0.1 % w/w, more preferably equal to or less than 0.05% w/w of calcium, based on the total weight of the medium.
- the acetate is present or supplied to the medium (also referred to herein as fermentation medium) as a disassociated or a non-disassociated acetate salt.
- the fermentation medium comprises an acetate salt, suitably a disassociated or a non-disassociated acetate salt.
- the acetate salt is an alkali metal or alkali earth metal salt of acetate.
- alkali or alkaline earth metal salt of acetate is selected from the group consisting of sodium acetate, potassium acetate, calcium acetate, or a mixture thereof.
- the alkali or alkaline earth metal salt of acetate is calcium acetate.
- the acetate is present as ammonium acetate.
- ammonium acetate may for example be represented with the chemical formula NH 4 CH 3 CO 2 [054] More preferably the acetate is present or supplied to the medium as a disassociated or a non-disassociated calcium acetate salt and/or a disassociated or a non-disassociated ammonium acetate salt, most preferably as a disassociated or a non-disassociated ammonium acetate salt.
- the acetate is added to the medium in the form of an aqueous solution or aqueous suspension or aqueous dispersion comprising acetate, optionally as an acetate anion or otherwise as a disassociated or a non-disassociated salt.
- the fermentation medium comprises an aqueous solution or aqueous suspension or aqueous dispersion comprising an ammonium acetate salt, suitably a disassociated or a nondisassociated ammonium acetate salt.
- the acetate may for example be added to the medium (also referred to herein as fermentation medium) before the start of the fermentation and/or during the fermentation. If acetate is added during the fermentation such acetate is preferably added in a continuous manner, for example by in-line addition, for example via a loop reactor.
- the acetate is present in the medium, for example at the start of the fermentation and/or during fermentation, in a concentration in the range from equal to or more than 0.4 gram/kilogram (gr/kg), preferably from equal to or more than 1 .0 gram/kilogram (gr/kg) , more preferably from equal to or more than 2.0 gr/kg, yet more preferably from equal to or more than 3.0 gr/kg, still more preferably from equal to or more than 4.0 gr/kg, to equal to or less than 60 gr/kg, preferably to equal to or less than 40 gr/kg, more preferably to equal to or less than 30 gr/kg, even more preferably to equal to or less than 20 gr/kg, still more preferably to equal to or less than 10 gr/kg, yet more preferably to equal to or less than 8.0 gr/kg and most preferably equal to or less than 6.0 gr/kg, wherein gr/kg refers to the weight in grams of acetate per total weight in kilograms of medium. In the above range the preference the preference
- the acetate is present in the medium, for example at the start of the fermentation and/or during fermentation, in a concentration in the range from equal to or more than 0.04% w/w, preferably from equal to or more than 0.10 % w/w, more preferably from equal to or more than 0.20% w/w, yet more preferably from equal to or more than 0.30% w/w, still more preferably from equal to or more than 0.40% w/w, to equal to or less than 6% w/w, preferably to equal to or less than 4% w/w, more preferably to equal to or less than 3% w/w, even more preferably to equal to or less than 2% w/w, still more preferably to equal to or less than 1 % w/w, yet more preferably to equal to or less than 0.80% w/w and most preferably equal to or less than 0.60% w/w, based on the total weight of medium.
- Acetate salts that have a low solubility in water may be less preferred as depending on the circumstances such may lead to precipitation. More preferred are acetate salts with a good solubility in water, such as ammonium acetate, potassium acetate and/or sodium acetate. Ammonium acetate is most preferred. Without wishing to be bound to any kind of theory it is believed the use of ammonium acetate may have less osmotic effects than for example sodium acetate or potassium actetate.
- the fermentation medium comprises in the range from equal to or more than 0.10% w/w, more preferably from equal to or more than 0.20% w/w, to equal to or less than 2.0 % w/w, more preferably equal to or less than 1 .0 % w/w of acetate, preferably in the form of ammonium acetate, based on the total weight of the medium.
- acetate is added as a salt, a solution, suspension or dispersion
- the above ranges apply to the weight of the amount of acetate “as such” therein, not to the weight of the salt, solution, suspension or dispersion as a whole.
- -pH adjusters such as ammoniumhydroxide, sodiumhydroxide or potassiumhydroxide; and/or -minerals such as manganese, magnesium and/or zinc and/or any associated or disassociated salt thereof.
- the medium at least comprises one or more nutrients such as a yeast and/or a pH adjuster such as ammoniumhydroxide, sodiumhydroxide and/or potassiumhydroxide.
- nutrients such as a yeast and/or a pH adjuster such as ammoniumhydroxide, sodiumhydroxide and/or potassiumhydroxide.
- the medium is an aqueous medium.
- the medium therefore most preferably also comprises water. Fermentation conditions, pH and temperature
- step (a) comprises fermenting the Lactobacillus rhamnosus in a lactose-free, preferably milk-free, medium in a fermentor, and removing a fermentation broth from the fermentor, wherein the fermentation is carried out at a temperature of equal to or less than 39°C, preferably equal to or less than 37°C and at a pH setpoint of equal to or less than 5.6, preferably equal to or less than 5.4.
- the fermentation is carried out at a temperature equal to or more than 15°C, more preferably equal to or more than 20°C, still more preferably equal to or more than 25°C, even more preferably equal to or more than 30°C, yet more preferably equal to or more than 32°C and most preferably equal to or more than 35°C.
- the fermentation is preferably carried out at a temperature equal to or less than 39°C, more preferably equal to or less than 38°C and most preferably equal to or less than 37°C.
- the fermentation is carried out at a pH point, preferably a pH setpoint, that is equal to or more than pH 3.0, more preferably equal to or more than pH 3.5, still more preferably equal to or more than pH 4.2, even more preferably equal to or more than pH 4.6, yet more preferably equal to or more than pH 4.8 and most preferably equal to or more than pH 5.0.
- the fermentation is preferably carried out at a pH point, preferably a pH setpoint, that is equal to or less than pH 5.6, more preferably equal to or less than pH 5.5 and most preferably equal to or less than pH 5.4.
- the pH setpoint is herein preferably understood to be a pH of the medium (herein also referred to as the fermentation medium) that is controlled by addition of a titrant, preferably a titrant selected from the group consisting of sodium hydroxide, potassium hydroxide and/or ammonium hydroxide. This advantageously allows one to direct the fermentation at/to this specific pH setpoint.
- a titrant preferably a titrant selected from the group consisting of sodium hydroxide, potassium hydroxide and/or ammonium hydroxide.
- fermentation is herein preferably understood the process until the fermentation broth is removed from the fermentor.
- the fermentation can be a continuous, semi-continous or batch-wise fermentation. If the fermentation is carried out batch-wise, the fermentation is preferably stopped by cooling, pH drop and/or depletion of the carbon source used as a feed whereafter conveniently the fermentation broth may be removed from the fermentor.
- the pH is maintained in the range from equal to or more than 5.4 to equal to or less than 5.6, whilst the temperature is maintained in the range from equal to or more than 37°C to equal to or less than 39°C.
- the pH of the fermentation medium is maintained at 5.6, whilst the temperature is maintained at 39°C.
- the pH is maintained at 5.4, whilst the temperature is maintained at 39°C.
- the pH is maintained at 5.6, whilst the temperature is maintained at 39°C.
- the pH is maintained at 5.4, whilst the temperature is maintained at 37°C.
- step (b) of the processes according to the invention shear is applied to the fermentation broth.
- the shear is suitably applied to a fermentation broth that has been removed from the fermentor.
- the processes according to the invention may comprise additional steps between step (a) and step (b). However, preferably step (b) is carried out on the fermentation broth as produced and/or obtained by step (a).
- the shear may advantageously be applied by mechanical treatment of the fermentation broth.
- Such mechanical treatment may for example comprise the subjection of the fermentation broth to a volumetric power input of 1 - 500 kW/m3, more preferably 1 - 200 kW/m3, even more preferably 1 - 100 kW/m3, preferably for a duration of 0.1 - 60 min, more preferably 1 - 30 min, and even more preferably 1 - 10 min.
- the mechanical treatment may preferably comprise or consist of a treatment with a mixer and/or a treatment with an homogenizer, and/or a treatment with a mill and/or a treatment with a centrifuge (including for example continous centrifuges with or without differential gravity). More preferably step (b) comprises or consists of the application and/or addition of mechanical shearing stress to the fermentation broth, preferably by one of the above exemplified mechanical treatments.
- shear forces are a common phenomenon.
- a shear force is understood to exist when there is a first force acting on (part of) a composition in a first direction, and a second force acting on (part of) the composition that is stationary or moving in a second non- aligned direction.
- Shear stress (often denoted by the Greek symbol “tau” or “r”) is the component of stress coplanar with a material cross section. lt arises from the shear force and more specifically from the component of force vector parallel to the material cross section. Average shear stress refers to the force applied per unit area and can be calculated with formula (I) below:
- Shear rate is the rate at which a progressive shearing deformation is applied. For a simple case, this can be the gradient of velocity in a flowing material. Shear rate is expressed in “reciprocal seconds, i.e. in “s“ 1 ".
- HSH high-shear homogenization
- the shear is applied to the fermentation broth after such fermentation broth has been removed from the fermentor and preferably before such fermentation broth has optionally been frozen, freeze-dried or encapsulated.
- a shear rate is applied in the range from equal to or more than 0.5 s -1 , preferably from equal to or more than 1 .0 s -1 , more preferably from equal to or more than 10 s’ 1 , yet more preferably from equal to or more than 100 s -1 , still more preferably from equal to or more than 500 s -1 , to equal to or less than 500000 s -1 , preferably equal to or less than 100000 s’ 1 , more preferably equal to or less than 50000 s’ 1 , yet more preferably equal to or less than 10000 s -1 , still more preferably equal to or less than 5000 s -1 .
- a shear stress is applied in the range from equal to or more than 1 ⁇ 10 9 Pascal, preferably from equal to or more than 1 ⁇ 10 8 Pascal, more preferably from equal to or more than 1 ⁇ 10 7 Pascal Pascal, yet more preferably from equal to or more than 1 ⁇ 10 6 Pascal, still more preferably from equal to or more than T 1 O’ 5 Pascal, to equal to or less than 1 ⁇ 10 1 Pascal, more preferably equal to or less than 1 ⁇ 10 2 Pascal, yet more preferably equal to or less than 1 ⁇ 10’ 3 Pascal, still more preferably equal to or less than 1 ⁇ 10’ 4 Pascal.
- step (b) may or may not comprise or consist of homogenization of the fermentation broth.
- step (b) comprises or consists of homogenization of the fermentation broth. If applied, homogenization can be applied to the fermentation broth before or after any optional concentration. Preferably any homogenization is applied before any optional (subsequent) concentration.
- step (b) comprises or consists of homogenization of the, preferably unconcentrated, fermentation broth
- homogenization is preferably carried out at a rate in the range from equal to or more than 1000 rounds per minute (rpm), more preferably from equal to or more than 3000 rounds per minute (rpm), yet more preferably from equal to or more than 5000 rounds per minute (rpm), still more preferably from equal to or more than 8000 rounds per minute (rpm), even still more preferably from equal to or more than 10000 rounds per minute (rpm), yet even more preferably from equal to or more than 11000 rounds per minute (rpm), most preferably from equal to or more than 12000 rounds per minute (rpm), to equal to or less than 50000 rounds per minute (rpm), more preferably equal to or less than 30000 rounds per minute (rpm), yet more preferably equal to or less than 23000 rounds per minute (rpm), still more preferably equal to or less than 18000 rounds per minute (rpm) and most preferably equal to or less than 16000 rounds per minute (rpm).
- step (b) comprises or consists of homogenization of the, preferably unconcentrated, fermentation broth
- homogenization is preferably carried out for a period (also referred to as duration) in the range from equal to or more than 0.5 minute, more preferably from equal to or more than 1 minute, yet more preferably from equal to or more than 2 minutes, and still more preferably from equal to or more than 3 minutes, yet still more preferably from equal to or more than 4 minutes to equal to or less than 30 minutes, more preferably equal to or less than 20 minutes, yet more preferably equal to or less than 10 minutes, still more preferably equal to or less than 7 minutes and most preferably equal to or less than 5 minutes.
- step (b) comprises or consists of homogenization of an unconcentrated fermentation broth, wherein such homogenization is carried out at a rate in the range from more than 10000 rounds per minute (rpm), more preferably from equal to or more than 11000 rounds, most preferably from equal to or more than 12000 rounds per minute (rpm), to equal to or less than 50000 rounds per minute (rpm), more preferably equal to or less than 30000 rounds per minute (rpm), for a period (also referred to as duration) in the range from equal to or more than 1 minute, yet more preferably from equal to or more than 2 minutes, and still more preferably from equal to or more than 3 minutes, yet still more preferably from equal to or more than 4 minutes to equal to or less than 30 minutes, more preferably equal to or less than 20 minutes, yet more preferably equal to or less than 10 minutes, still more preferably equal to or less than 7 minutes and most preferably equal to or less than 5 minutes.
- step (b) may or may not comprise or consist of centrifugation of the fermentation broth.
- centrifugation is preferably carried out at a centrifugation rate in the range from equal to or more than 500 rounds per minute (rpm), more preferably from equal to or more than 800 rounds per minute (rpm), yet more preferably from equal to or more than 1000 rounds per minute (rpm), still more preferably from equal to or more than 1500 rounds per minute (rpm), and most preferably from equal to or more than 2000 rounds per minute (rpm), to equal to or less than 30000 rounds per minute (rpm), more preferably equal to or less than 20000 rounds per minute (rpm), yet more preferably equal to or less than 16000 rounds per minute (rpm), still more preferably equal to or less than 10000 rounds per minute (rpm) and most preferably equal to or less than 8000 rounds per minute (rpm).
- step (b) comprises or consists of centrifugation of the fermentation broth
- centrifugation is preferably carried out for a period (also referred to as duration) in the range from equal to or more than 0.5 minute, more preferably from equal to or more than 1 minute, yet more preferably from equal to or more than 2 minutes, and still more preferably from equal to or more than 3 minutes, to equal to or less than 30 minutes, more preferably equal to or less than 20 minutes, yet more preferably equal to or less than 10 minutes, still more preferably equal to or less than 7 minutes and most preferably equal to or less than 5 minutes.
- the fermentation broth may suitably be concentrated by a factor of equal to or less than 1000, more suitably equal to or less than 200, even more suitably equal to or less than 100.
- step (b) comprises concentration of the fermentation broth, most preferably by centrifugation, and the fermentation broth is concentrated until a concentration factor is reached of equal to or more than 10, more preferably equal to or more than 12.
- step (b) may comprise or consist of homogenization of the fermentation broth, optionally filtration of the fermentation broth, and subsequent centrifugation of the, suitably homogenized, fermentation broth. Preferences for the homogenization and centrifugation are as indicated above.
- step (b) comprises or consists of homogenization and centrifugation of the fermentation broth
- centrifugation preferably allows for a further concentration of the fermentation broth as indicated above. Most preferably such further concentration is carried out until a concentration factor is reached of equal to or more than 8, more preferably equal to or more than 10 and even more preferably equal to or more than 12.
- step (b) thus preferably produces a composition comprising Lactobacillus rhamnosus cells, wherein equal to or more than 90% w/w, preferably equal to or more than 95% w/w, more preferably equal to or more than 99% w/w, yet more preferably equal to or more than 99.5% w/w, still more preferably equal to or more than 99.9% w/w and most preferably still more preferably equal to or more than 100.0% w/w of the bacterial particles have a particle size, as determined by laser diffraction particle size analysis, of equal to or less than 8.0 micrometer (pm), preferably equal to or less than 7.5 micrometer, more preferably equal to or less than 7.0 micrometer, yet more preferably equal to or less than 6.5 micrometer and most preferably equal to or less than 6.0 micrometer, preferably equal or less than 5.5, 5.0, 4.5, 4.0, 3.5, 3.0, 2.5, or 2.0 micrometer, and the composition preferably comprises
- step (b) may suitably result in a sheared and/or concentrated fermentation broth, more preferably in an homogenized and/or filtrated and/or centrifugated fermentation broth.
- the invention also provides a process for the production of a Lactobacillus rhamnosus, respectively Lactobacillus rhamnosus cells, respectively a composition comprising a Lactobacillus rhamnosus, respectively Lactobacillus rhamnosus cells, wherein the process comprises the steps of:
- drying methods include vacuum drying, infrared convection drying, microwaving, freeze-drying and/or spray-drying. Combinations of these are also possible.
- step (c) comprises spray-drying or freeze-drying of the concentrated fermentation broth.
- step (c) preferably comprises freezing and subsequent freeze-drying of a sheared and concentrated fermentation broth, resulting from, respectively produced or obtained by, step (b).
- step (b) results in, respectively produces an, an homogenized and/or filtrated and/or centrifugated fermentation broth.
- step (c) comprises spray-drying; freezing; or freezing and freeze-drying of an homogenized and/or filtrated and/or centrifugated fermentation broth resulting from, respectively produced or obtained by, step (b).
- step (a) preferably after step (a) but before step (c) one or more additives, preferably cryoprotectants and/or stabilizers, may be added. More preferably such cryoprotectants and/or stabilizers are added to the sheared and concentrated fermentation broth, preferably to an homogenized and/or filtrated and/or centrifugated fermentation broth. Such sheared and concentrated fermentation broth, preferably homogenized and/or filtrated and/or centrifugated fermentation broth, is conveniently resulting from, respectively produced or obtained by, step (b). Hence preferably any cryoprotectants and/or stabilizers are added subsequent to step (b) and before step (c). However, if so desired, any cryoprotectants and/or stabilizers may also be added after step (a) and before step (b).
- any cryoprotectants and/or stabilizers may also be added after step (a) and before step (b).
- cryoprotectants or stabilizers include, but are not limited to, glucose, lactose, raffinose, sucrose, trehalose, adonitol, starch maltodextrin, glycerol, mannitol sorbitol, plolypropylene glycol, polyethylene glycol, ribitol alginate, bovine serum albumin, carnitine, citrate, cystein, dextran, dimethyl sufoxide, sodium glutamate, glycin, betaine, glycogen, hypotaurin, skimmed milk peptone, polyvinyl pirrolidine, taurine, nucleosides, nucleotides and any combinations thereof.
- Lactobacillus rhamnosus bacterial particles or a composition comprising Lactobacillus rhamnosus bacterial particles preferably obtained or obtainable by the processes described above.
- Lactobacillus rhamnosus bacterial particles wherein preferably equal to or more than 90% w/w, preferably equal to or more than 95% w/w, more preferably equal to or more than 99% w/w, yet more preferably equal to or more than 99.5% w/w, still more preferably equal to or more than 99.9% w/w and most preferably still more preferably equal to or more than 100.0% w/w of the bacterial particles have a particle size, as suitably determined by laser diffraction particle size analysis, of equal to or less than 8.0 micrometer, preferably equal to or less than 7.5 micrometer, more preferably equal to or less than 7.0 micrometer, yet more preferably equal to or less than 6.5 micrometer and most preferably equal to or less than 6.0 micrometer, preferably equal or less than 5.5, 5.0, 4.5, 4.0, 3.5, 3.0, 2.5, or 2.0 micrometer, and the bacterial particles preferably have a cell viability, respectively viable cell count, of equal
- a composition comprising Lactobacillus rhamnosus bacterial particles, wherein preferably equal to or more than 90% w/w, preferably equal to or more than 95% w/w, more preferably equal to or more than 99% w/w, yet more preferably equal to or more than 99.5% w/w, still more preferably equal to or more than 99.9% w/w and most preferably still more preferably equal to or more than 100.0% w/w of the bacterial particles have a particle size, as suitably determined by laser diffraction particle size analysis, of equal to or less than 8.0 micrometer, preferably equal to or less than 7.5 micrometer, more preferably equal to or less than 7.0 micrometer, yet more preferably equal to or less than 6.5 micrometer and most preferably equal to or less than 6.0 micrometer, preferably equal or less than 5.5, 5.0, 4.5, 4.0, 3.5, 3.0, 2.5, or 2.0 micrometer, and the composition preferably comprises cell viability, respectively viable cell count, of equal
- the Lactobacillus rhamnosus bacterial particles have a particle size distribution, as suitably determined by laser diffraction particle size analysis, wherein the particle size distribution is bimodal. That is, preferably such particle size distribution has two peaks, a first peak (“peak 1”) in particles with a particle size equal to or smaller than 2.0 micrometer and a second peak (“peak 2”) in particles having a particle size equal to or larger than 2.0 micrometer. That is, the Lactobacillus rhamnosus bacterial particles preferably have a biomodal particle size distribution, as suitably determined by laser diffraction parties size analysis, wherein a first peak (“peak 1”) is situationed before 2.0 micrometer and a second peak (“peak 2”) is situated after 2.0 micrometer.
- the ratio of the peak area of peak 1 to the peak area of peak 2 is a ratio in the range from 3:1 to 5:1 , more preferably about 4:1. That is, the Lactobacillus rhamnosus bacterial particles preferably have a biomodal particle size distribution, as suitably determined by laser diffraction parties size analysis, wherein equal to or more than 75%, preferably equal to or more than 76%, more preferably equal to or more than 77%, even more preferably equal to or more than 78% w/w, yet more preferably equal to or more than 79%, still more preferably equal to or more than 80%, yet still more preferably equal to or more than 81 %, even still more preferably equal to or more than 82% and most preferably preferably equal to or more than 83% of the particles, have a particle size of equal to or less than 2.0 micrometer.
- the remaining Lactobacillus rhamnosus bacterial particles in the biomodal particle size distribution i.e. the particles that have a particle size of more than 2.0 micrometer in the biomodal particle size distribution, have a particle size distribution wherein equal to or more than 90%, preferably equal to or more than 95%, more preferably equal to or more than 99%, yet more preferably equal to or more than 99.5% , still more preferably equal to or more than 99.9% and most preferably still more preferably equal to or more than 100.0% of these bacterial particles (i.e.
- these particles having a particles size of more than 2.0 micrometer have a particle size, as suitably determined by laser diffraction particle size analysis, of equal to or less than 8.0 micrometer, preferably equal to or less than 7.5 micrometer, more preferably equal to or less than 7.0 micrometer, yet more preferably equal to or less than 6.5 micrometer and most preferably equal to or less than 6.0 micrometer.
- compositions further comprise one or more additives, preferably cryoprotectants and/or stabilizers.
- cryoprotectants or stabilizers include, but are not limited to, glucose, lactose, raffinose, sucrose, trehalose, adonitol, starch maltodextrin, glycerol, mannitol sorbitol, plolypropylene glycol, polyethylene glycol, ribitol alginate, bovine serum albumin, carnitine, citrate, cystein, dextran, dimethyl sufoxide, sodium glutamate, glycin, betaine, glycogen, hypotaurin, skimmed milk peptone, polyvinyl pirrolidine, taurine, nucleosides, nucleotides and any combinations thereof.
- compositions are lactose-free composition, more preferably the compositions are milk-free compositions.
- compositions may further comprise calcium or a calcium salt and/or acetate or an acetate salt.
- a composition for animal and/or human consumption preferably a medicament or a food product or a beverage product, comprising:
- composition comprising Lactobacillus rhamnosus bacterial particles as described above.
- Lactobacillus rhamnosus bacterial particles as described above or the composition comprising Lactobacillus rhamnosus bacterial particles as described above in a probiotic composition and/or for medical purposes and/or in or as a medicament preferably for use as a medicament for the treatment of or for prevention of a disease or condition in or related to the animal or human gastro-intestinal tract.
- the term "food product” is intended to encompass any consumable matter. Hence, it may be a product intended for the consumption by humans, but the term also encompasses products to be consumed by animals
- the food or beverage product is a dairy product, preferably a yoghurt, a cheese, a butter, a buttermilk, quark, a sour cream, a kefir, a twarog, a fermented whey-based beverage, a koumiss, a milk beverage, a yoghurt drink, a fermented milk, a matured cream, a fromage frais, a milk, a dairy product retentate, a processed cheese, a cottage cheese, a cream dessert, or infant milk.
- composition obtained or obtainable by the process as described herein or the compositions as described herein may be added to other components to create composition for use as probiotics and/or prebiotics. They may be used a direct fed microbials in food or feed for humans or animals. The probiotics and/or prebiotics may be used as a food or feed additive for humans or animals.
- the invention provides for a probiotic comprising or consisting of Lactobacillus rhamnosus bacterial particles, respectively a composition comprising or consisting of Lactobacillus rhamnosus bacterial particles as described herein, and preferably calcium or a calcium salt and/or acetate or an acetate salt.
- probiotic is intended to refer to any micro-organism that is wished to be consumed owing to any beneficial effect it may have on its consumer.
- the composition obtained or obtainable by the process as described herein or the composition as described herein is a pharmaceutical composition, in such embodiments the composition optionally comprises a pharmaceutically acceptable excipient.
- the composition obtained or obtainable by the process as described herein or the composition or probiotic as described herein for use as a medicament preferably for the treatment of gastro-intestinal disorders and/or to improve gut health, for example to improve symptoms of irritable bowel syndrome and/or to improve digestive health and/or strengthen the immune system.
- the invention provides for a use of the composition obtained or obtainable by the process as described herein or the composition as describe herein in a food or beverages product.
- a decimal dilution range was made by pipetting 1 ml +/-0.01 ml of the initial suspension into a tube with 9 ml sterile PSW solution using a sterile disposable serological 2 ml pipette. For each dilution step a new pipette was used. It was ensured that there were no air bubbles present and that there were no drops falling out or sticking to the side of the pipette. Subsequently the total was mixed by vortexing until a homogenous suspension was obtained. The above steps were repeated until the desired dilutions were reached.
- PSW Peptone Salt Water
- the agar was allowed to solidify and the petri dishes were incubated upside down at the appropriate conditions specific for 2-3 days at 37°C. The plates were protected during incubation against dehydration. Anaerobic conditions were obtained by incubating the petri dishes in an anaerobic jar with AnaeroGen packs (Oxoid) in accordance with the manufacturing’s instructions. An CO 2 indicator strip was added for verification.
- CFU colony forming units
- the bacterial particle size distribution of fermentation samples was analysed by using a Laser Diffraction Particle Size Analyzer (LS 13 320 by Beckman Coulter) in line with the provided manual. If so desired, the Fraunhofer optical model can be used for determining the bacterial particle size (pm). For all samples, the bacterial particle size was recorded over a range from 0.4 to 20pm and the outcome was expressed as volume (%) whereby the sum of all size sizes added up to 100%. In each case 0.65ml of fermentation broth was added to the sample port and the sample was subsequently analysed. The vessel contained 0.85% NaCI. A graph was generated wherein for all sample fractions the cell size was expressed on the x- axis ranging from 0.4 to 20pm, the volume (%) was expressed on the y-axis.
- LS 13 320 Laser Diffraction Particle Size Analyzer
- a Lactobacillus rhamnosus GG strain (derived from deposit ATCC 53103 as mentioned above) was added to several (separate) fermentors. In each fermentor the Lactobacillus rhamnosus GG strain was fermented in a fermentation medium comprising the components as listed in Table 1 under the conditions as listed in Table 1. During the fermentation glucose as listed in Table 1 was used as (carbohydrate) feed and the Lactobacillus rhamnosus GG was allowed to ferment this glucose. When the glucose was depleted, samples were taken. At the moment of sample taking samples were split up in two fractions:
- the overall bacterial particle size is much smaller after the application of the claimed fermentation conditions and shear which allows for a higher amount of bacterial particles per gram.
- Table 1 Fermentation medium components and fermentation medium conditions.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202480037804.0A CN121666445A (en) | 2023-06-08 | 2024-06-10 | Novel method for producing lactobacillus rhamnosus |
| EP24730714.3A EP4724559A1 (en) | 2023-06-08 | 2024-06-10 | Novel process for producing lactobacillus rhamnosus |
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23178308.5 | 2023-06-08 | ||
| EP23178309.3 | 2023-06-08 | ||
| EP23178308 | 2023-06-08 | ||
| EP23178307.7 | 2023-06-08 | ||
| EP23178309 | 2023-06-08 | ||
| EP23178307 | 2023-06-08 | ||
| EP23178555.1 | 2023-06-09 | ||
| EP23178554.4 | 2023-06-09 | ||
| EP23178556 | 2023-06-09 | ||
| EP23178556.9 | 2023-06-09 | ||
| EP23178555 | 2023-06-09 | ||
| EP23178554 | 2023-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024252017A1 true WO2024252017A1 (en) | 2024-12-12 |
Family
ID=91375699
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2024/065886 Ceased WO2024252018A1 (en) | 2023-06-08 | 2024-06-10 | Novel process for producing lactobacillus rhamnosus |
| PCT/EP2024/065887 Ceased WO2024252019A1 (en) | 2023-06-08 | 2024-06-10 | Novel process for producing lactobacillus rhamnosus |
| PCT/EP2024/065885 Ceased WO2024252017A1 (en) | 2023-06-08 | 2024-06-10 | Novel process for producing lactobacillus rhamnosus |
| PCT/EP2024/065888 Ceased WO2024252020A1 (en) | 2023-06-08 | 2024-06-10 | Novel process for producing lactobacillus rhamnosus |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2024/065886 Ceased WO2024252018A1 (en) | 2023-06-08 | 2024-06-10 | Novel process for producing lactobacillus rhamnosus |
| PCT/EP2024/065887 Ceased WO2024252019A1 (en) | 2023-06-08 | 2024-06-10 | Novel process for producing lactobacillus rhamnosus |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2024/065888 Ceased WO2024252020A1 (en) | 2023-06-08 | 2024-06-10 | Novel process for producing lactobacillus rhamnosus |
Country Status (3)
| Country | Link |
|---|---|
| EP (4) | EP4724560A1 (en) |
| CN (3) | CN121646635A (en) |
| WO (4) | WO2024252018A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140147427A1 (en) * | 2011-06-08 | 2014-05-29 | Organobalance Gmbh | Spray-Dried Lactobacillus Stems/Cells and the Use of Same Against Helicobacter Pylori |
| CN106011196A (en) * | 2016-05-19 | 2016-10-12 | 厦门大学 | Method for purifying lactobacillus rhamnosus extracellular polysaccharides |
| CN108042578A (en) * | 2018-02-18 | 2018-05-18 | 王甲林 | A kind of health care vaginal jellies containing compound probiotic ingredient |
| WO2018101612A1 (en) * | 2016-12-02 | 2018-06-07 | 주식회사 락토메이슨 | Method for controlling size of lactobacillus using membrane filter |
| CN110150526A (en) * | 2019-06-12 | 2019-08-23 | 上海紫微健康管理有限责任公司 | Solid beverage and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2398890T3 (en) | 2009-02-23 | 2015-08-17 | Chr Hansen As | A process for preparing lactic acid bacterial preparation |
| CA3085456A1 (en) * | 2017-12-14 | 2019-06-20 | Pure Cultures 2020, Inc. | Probiotics and fermentation metabolites for the prevention and treatment of disease conditions in animals |
| JP2020137456A (en) * | 2019-02-28 | 2020-09-03 | ビオフェルミン製薬株式会社 | Culture medium for culture of lactic acid bacteria |
| CN111826324A (en) * | 2020-08-05 | 2020-10-27 | 厦门惠盈动物科技有限公司 | Preparation method of lactobacillus rhamnosus powder |
| CN117535203A (en) * | 2023-12-21 | 2024-02-09 | 中粮生物科技股份有限公司 | Mixed inoculants and their preparation methods and applications |
-
2024
- 2024-06-10 EP EP24730715.0A patent/EP4724560A1/en active Pending
- 2024-06-10 EP EP24730714.3A patent/EP4724559A1/en active Pending
- 2024-06-10 WO PCT/EP2024/065886 patent/WO2024252018A1/en not_active Ceased
- 2024-06-10 EP EP24730716.8A patent/EP4724561A1/en active Pending
- 2024-06-10 CN CN202480037751.2A patent/CN121646635A/en active Pending
- 2024-06-10 EP EP24730717.6A patent/EP4724562A1/en active Pending
- 2024-06-10 WO PCT/EP2024/065887 patent/WO2024252019A1/en not_active Ceased
- 2024-06-10 CN CN202480037804.0A patent/CN121666445A/en active Pending
- 2024-06-10 WO PCT/EP2024/065885 patent/WO2024252017A1/en not_active Ceased
- 2024-06-10 CN CN202480037789.XA patent/CN121358845A/en active Pending
- 2024-06-10 WO PCT/EP2024/065888 patent/WO2024252020A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140147427A1 (en) * | 2011-06-08 | 2014-05-29 | Organobalance Gmbh | Spray-Dried Lactobacillus Stems/Cells and the Use of Same Against Helicobacter Pylori |
| CN106011196A (en) * | 2016-05-19 | 2016-10-12 | 厦门大学 | Method for purifying lactobacillus rhamnosus extracellular polysaccharides |
| WO2018101612A1 (en) * | 2016-12-02 | 2018-06-07 | 주식회사 락토메이슨 | Method for controlling size of lactobacillus using membrane filter |
| CN108042578A (en) * | 2018-02-18 | 2018-05-18 | 王甲林 | A kind of health care vaginal jellies containing compound probiotic ingredient |
| CN110150526A (en) * | 2019-06-12 | 2019-08-23 | 上海紫微健康管理有限责任公司 | Solid beverage and preparation method thereof |
Non-Patent Citations (10)
| Title |
|---|
| "Functional Analysis of Lactobacillus rhamnosus GG Pili in Relation to Adhesion and Immunomodulatory Interactions with Intestinal Epithelial Cells", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 78, no. 1, January 2012 (2012-01-01), pages 185 - 193 |
| "The determination of viable counts in probiotic cultures microencapsulated by spray-coating", FOOD MICROBIOLOGY, vol. 24, 2010, pages 1104 - 1111 |
| CLAUDE P CHAMPAGNE ET AL: "The determination of viable counts in probiotic cultures microencapsulated by spray-coating", FOOD MICROBIOLOGY, ACADEMIC PRESS LTD, LONDON, GB, vol. 27, no. 8, 20 July 2010 (2010-07-20), pages 1104 - 1111, XP028362392, ISSN: 0740-0020, [retrieved on 20100724], DOI: 10.1016/J.FM.2010.07.017 * |
| DING W.K. ET AL: "Effect of Homogenization Techniques on Reducing the Size of Microcapsules and the Survival of Probiotic Bacteria Therein", JOURNAL OF FOOD SCIENCE, vol. 74, no. 6, 31 July 2009 (2009-07-31), US, XP093106967, ISSN: 0022-1147, DOI: 10.1111/j.1750-3841.2009.01195.x * |
| GOMAND FAUSTINE ET AL: "Shaving and breaking bacterial chains with a viscous flow", vol. 16, no. 40, 21 October 2020 (2020-10-21), GB, pages 9273 - 9291, XP093105300, ISSN: 1744-683X, Retrieved from the Internet <URL:https://pubs.rsc.org/en/content/articlepdf/2020/sm/d0sm00292e> DOI: 10.1039/D0SM00292E * |
| ME. HOWEVER: "Recommendations for the viability assessment of probiotics as concentrated cultures and in food matrices", INT. J. FOOD MICROBIOLY, vol. 149, 2011, pages 185 - 193, XP028263254, DOI: 10.1016/j.ijfoodmicro.2011.07.005 |
| NG I-SON ET AL: "Enhanced exopolysaccharide production and biological activity ofLactobacillus rhamnosusZY with calcium and hydrogen peroxide", PROCESS BIOCHEMISTRY, ELSEVIER LTD, GB, vol. 52, 5 October 2016 (2016-10-05), pages 295 - 304, XP029876113, ISSN: 1359-5113, DOI: 10.1016/J.PROCBIO.2016.10.006 * |
| VAN LOON JACK ET AL: "Centrifuges and inertial shear forces", JOURNAL OF GRAVITATIONAL PHYSIOLOGY, vol. 11, no. 1, 1 March 2004 (2004-03-01), United States, pages 29 - 38, XP093105123 * |
| WANG TAO ET AL: "Fermentation optimization and kinetic model for high cell density culture of a probiotic microorganism:LS-8", BIOPROCESS AND BIOSYSTEMS ENGINEERING, SPRINGER, DE, vol. 43, no. 3, 11 November 2019 (2019-11-11), pages 515 - 528, XP037015011, ISSN: 1615-7591, [retrieved on 20191111], DOI: 10.1007/S00449-019-02246-Y * |
| WASKO A. ET AL: "The Plackett-Burman design in optimization of media components for biomass production of Lactobacillus rhamnosus OXY", ACTA BIOLOGICA HUNGARICA., vol. 61, no. 3, 1 September 2010 (2010-09-01), HU, pages 344 - 355, XP093107963, ISSN: 0236-5383, DOI: 10.1556/ABiol.61.2010.3.10 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN121666445A (en) | 2026-03-13 |
| WO2024252019A1 (en) | 2024-12-12 |
| CN121646635A (en) | 2026-03-10 |
| WO2024252018A1 (en) | 2024-12-12 |
| EP4724559A1 (en) | 2026-04-15 |
| CN121358845A (en) | 2026-01-16 |
| EP4724562A1 (en) | 2026-04-15 |
| EP4724560A1 (en) | 2026-04-15 |
| EP4724561A1 (en) | 2026-04-15 |
| WO2024252020A1 (en) | 2024-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4187321A (en) | Method for producing foods and drinks containing bifidobacteria | |
| Vasiljevic et al. | Production of β-galactosidase for lactose hydrolysis in milk and dairy products using thermophilic lactic acid bacteria | |
| Bury et al. | Disruption of Lactobacillus delbrueckii ssp. bulgaricus 11842 cells for lactose hydrolysis in dairy products: a comparison of sonication, high-pressure homogenization and bead milling | |
| CN101378662B (en) | Method of producing fermented milk using novel lactic acid bacterium | |
| JP4862053B2 (en) | New lactic acid bacteria | |
| Doleyres et al. | Bifidobacterium longum ATCC 15707 cell production during free-and immobilized-cell cultures in MRS-whey permeate medium | |
| CN108102987B (en) | Preparation of lactobacillus reuteri SS23-52 and dry powder leavening agent thereof and application of lactobacillus reuteri SS23-52 in pure probiotic yogurt | |
| CN110607255B (en) | Preparation method and application of lactobacillus delbrueckii and direct vat set lactobacillus delbrueckii starter | |
| EP3291686B1 (en) | Acid whey with stable lactose content | |
| US20150246081A1 (en) | Probiotics with methods for growth and use separately and in combination | |
| CN108330082A (en) | One plant of Lactobacillus paracasei and its application | |
| KR100500875B1 (en) | Bifidobacterium-fermented milk and process for producing the same | |
| WO2015063282A1 (en) | Use of algae to increase the viable active biomass of lactic acid bacteria | |
| WO2024252017A1 (en) | Novel process for producing lactobacillus rhamnosus | |
| JP2012105577A (en) | Production method of whey fermented beverage | |
| EP2837292B1 (en) | Synbiotic food composition containing tagatose and probiotic lactic acid bacteria | |
| AU2018322807A1 (en) | Process for producing an improved mesophilic fermented milk product | |
| JP4794592B2 (en) | New lactic acid bacteria | |
| Muigei et al. | Production of exopolysaccharides in the Kenyan fermented milk, Mursik | |
| Beitane et al. | The study of added prebiotics on b group vitamins concentration during milk fermentation | |
| Kowalska et al. | Characterization of Fermented Milks After the Passaging Process of Starter Cultures | |
| Adamu-Governor et al. | Effect of gum producing lactic acid bacteria from palm sap on the quality attributes of yoghurt | |
| Martins et al. | Improving galacto-oligosaccharide content in the production of lactose-reduced yogurt | |
| RU2622078C1 (en) | Method for combined enzyme beta-galactosidase production | |
| Phetsomphou et al. | Dairy Foods: Microbiology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24730714 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024730714 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2024730714 Country of ref document: EP Effective date: 20260108 |
|
| ENP | Entry into the national phase |
Ref document number: 2024730714 Country of ref document: EP Effective date: 20260108 |
|
| ENP | Entry into the national phase |
Ref document number: 2024730714 Country of ref document: EP Effective date: 20260108 |
|
| ENP | Entry into the national phase |
Ref document number: 2024730714 Country of ref document: EP Effective date: 20260108 |
|
| ENP | Entry into the national phase |
Ref document number: 2024730714 Country of ref document: EP Effective date: 20260108 |
|
| WWP | Wipo information: published in national office |
Ref document number: 2024730714 Country of ref document: EP |

